Combined therapy with sitagliptin plus granulocyte-colony stimulating factor in patients with acute myocardial infarction - Long-term results of the SITAGRAMI trial

International Journal of Cardiology

Volumn 215, Issue , 2016, Pages 441-445

  Gross, Lisa ^a   Theiss, Hans Diogenes ^a   Grabmaier, Ulrich ^a   Adrion, Christine ^b   Mansmann, Ulrich ^b   Sohn, Hae Young ^a   Hoffmann, Ellen ^c   Steinbeck, Gerhard ^a   Franz, Wolfgang Michael ^a,d   Brenner, Christoph ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c KLINIKUM BOGENHAUSEN   (Germany)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Acute myocardial infarction; Clinical studies; Dipeptidylpeptidase IV; Granulocyte colony stimulating factor; Progenitor cell therapy; Sitagliptin

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; SITAGLIPTIN;

ACUTE HEART INFARCTION; ARTICLE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS GRAFT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEW YORK HEART ASSOCIATION CLASS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME;

EID: 84964504905     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.04.134     Document Type: Article

References (30)

1. K. Moazzami, A. Roohi, and B. Moazzami Granulocyte colony stimulating factor therapy for acute myocardial infarction Cochrane Database Syst. Rev. 5 2013 CD008844
2. M.G. Engelmann, and et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (granulocyte colony-stimulating factor ST-segment elevation myocardial infarction) trial J. Am. Coll. Cardiol. 48 8 2006 1712 1721
3. B. Steppich, and et al. Stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute myocardial infarction. Long-term results of the REVIVAL-2 trial Thromb. Haemost. 115 4 2016
4. M.M. Zaruba, and et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction Cell Stem Cell 4 4 2009 313 323
5. H.D. Theiss, and et al. Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction Int. J. Cardiol. 168 4 2013 3359 3369
6. H.D. Theiss, and et al. Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis Stem Cell Res. 7 3 2011 244 255
7. L. Gross, and et al. FDG-PET reveals improved cardiac regeneration and attenuated adverse remodelling following Sitagliptin + G-CSF therapy after acute myocardial infarction Eur. Heart J. Cardiovasc. Imaging 17 2 2016 136 145
8. C. Brenner, and et al. Sitagliptin plus granulocyte colony-stimulating factor in patients suffering from acute myocardial infarction: a double-blind, randomized placebo-controlled trial of efficacy and safety (SITAGRAMI trial) Int. J. Cardiol. 205 2016 23 30
9. S.A. Fisher, and et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure Cochrane Database Syst. Rev. 4 2014 CD007888
10. H.D. Theiss, and et al. Safety and efficacy of SITAgliptin plus granulocyte-colony-stimulating factor in patients suffering from acute myocardial infarction (SITAGRAMI-trial) - rationale, design and first interim analysis Int. J. Cardiol. 145 2 2010 282 284
11. L.G. Shewan, and A.J. Coats Adherence to ethical standards in publishing scientific articles: a statement from the International Journal of Cardiology Int. J. Cardiol. 161 3 2012 124 125
12. J.B. Green, and et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N. Engl. J. Med. 373 3 2015 232 242
13. B.M. Scirica, and et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N. Engl. J. Med. 369 14 2013 1317 1326
14. W.B. White, and et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes N. Engl. J. Med. 369 14 2013 1327 1335
15. F. Zannad, and et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial Lancet 385 9982 2015 2067 2076
16. Yuichi J. Shimada, C.P. C., Liu Yuyin, Wilson Craig, Kupfer Stuart, Menon Venu, William C. Cuschman, Cyrus R. Mehta, George L. Bakris, Zannad Faeiz, and William B. White Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the examine trial Am. Heart J. 2016
17. D.Y. Chen, and et al. Sitagliptin after ischemic stroke in type 2 diabetic patients: a nationwide cohort study Medicine (Baltimore) 94 28 2015 e1128
18. K. Akita, and et al. Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice J. Am. Heart Assoc. 4 3 2015 e001469
19. C. Brenner, and et al. Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells Int. J. Cardiol. 177 1 2014 266 275
20. G. Chang, and et al. Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model Eur. J. Pharmacol. 718 1-3 2013 105 113
21. C. Brenner, and et al. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages Int. J. Cardiol. 199 2015 163 169
22. A.J. Scheen, N. Esser, and N. Paquot Antidiabetic agents: potential anti-inflammatory activity beyond glucose control Diabete Metab. 41 3 2015 183 194
23. T. Mita, and et al. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE): a randomized controlled trial Diabetes Care 2016
24. S. Ishikawa, and et al. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus Am. J. Cardiol. 114 3 2014 384 388
25. G.P. Fadini, and et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha Diabetes Care 33 7 2010 1607 1609
26. G. Savarese, and et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis Int. J. Cardiol. 181 2015 239 244
27. C. Steinwender, and et al. Late stent thrombosis after transcoronary transplantation of granulocyte-colony stimulating factor-mobilized peripheral blood stem cells following primary percutaneous intervention for acute myocardial infarction Int. J. Cardiol. 122 3 2007 248 249
28. B.E. Shaw, and et al. A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies Bone Marrow Transplant. 50 3 2015 334 340
29. M. Martino, and et al. Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear? Expert. Opin. Biol. Ther. 12 5 2012 609 621
30. V. Moalic Mobilization and collection of peripheral blood stem cells in healthy donors: risks, adverse events and follow-up Pathol. Biol. (Paris) 61 2 2013 70 74